Market Opportunity

New Global Infrastructure to Meet Future Industry Growth Needs

The global demand for clinical radioisotopes used for diagnostic imaging as well as a growing new category of radiotherapeutics that specifically target and destroy cancer cells is exceeding the global supply.

This situation is projected to worsen over the next decade as radioisotope-producing reactors are decommissioned due to age, unplanned outages, inefficiencies and a lack of new production capacity coming online. Other than Eden, no other nuclear reactors optimized for medical isotope production are known to be on the NRC’s approval roadmap, thereby favorably positioning Eden to be in the right place at the right time when production begins in late 2028.